JP2013531070A5 - - Google Patents

Download PDF

Info

Publication number
JP2013531070A5
JP2013531070A5 JP2013520827A JP2013520827A JP2013531070A5 JP 2013531070 A5 JP2013531070 A5 JP 2013531070A5 JP 2013520827 A JP2013520827 A JP 2013520827A JP 2013520827 A JP2013520827 A JP 2013520827A JP 2013531070 A5 JP2013531070 A5 JP 2013531070A5
Authority
JP
Japan
Prior art keywords
oxadiazol
benzyl
ethyl
acid
azetidinecarboxylic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013520827A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013531070A (ja
JP5788507B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/044597 external-priority patent/WO2012012477A1/en
Publication of JP2013531070A publication Critical patent/JP2013531070A/ja
Publication of JP2013531070A5 publication Critical patent/JP2013531070A5/ja
Application granted granted Critical
Publication of JP5788507B2 publication Critical patent/JP5788507B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013520827A 2010-07-20 2011-07-20 置換3−フェニル−1,2,4−オキサジアゾール化合物 Expired - Fee Related JP5788507B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36592310P 2010-07-20 2010-07-20
US61/365,923 2010-07-20
PCT/US2011/044597 WO2012012477A1 (en) 2010-07-20 2011-07-20 Substituted 3-phenyl-1,2,4-oxadiazole compounds

Publications (3)

Publication Number Publication Date
JP2013531070A JP2013531070A (ja) 2013-08-01
JP2013531070A5 true JP2013531070A5 (enExample) 2015-07-23
JP5788507B2 JP5788507B2 (ja) 2015-09-30

Family

ID=44628993

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013520827A Expired - Fee Related JP5788507B2 (ja) 2010-07-20 2011-07-20 置換3−フェニル−1,2,4−オキサジアゾール化合物

Country Status (6)

Country Link
US (1) US8822510B2 (enExample)
EP (1) EP2595969B1 (enExample)
JP (1) JP5788507B2 (enExample)
CN (1) CN103124727B (enExample)
ES (1) ES2539256T3 (enExample)
WO (1) WO2012012477A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012040532A1 (en) * 2010-09-24 2012-03-29 Bristol-Myers Squibb Company Substituted oxadiazole compounds and their use as s1p1 agonists
JP2013544811A (ja) 2010-11-03 2013-12-19 ブリストル−マイヤーズ スクイブ カンパニー 自己免疫疾患および血管疾患の治療用のs1p1アゴニストとしての複素環式化合物
UA114915C2 (uk) 2012-07-02 2017-08-28 Монсанто Текнолоджи Ллс Спосіб одержання 3,5-дизаміщених 1,2,4-оксадіазолів (варіанти)
US8957051B2 (en) * 2012-10-04 2015-02-17 Allergan, Inc. Bicyclic 1, 2, 4-oxadiazoles derivatives as sphingosine-1 phosphate receptors modulators
US8859598B2 (en) 2012-10-04 2014-10-14 Allergan, Inc. 1, 2, 4-oxadiazoles azetidine derivatives as sphingosine-1 phosphate receptors modulators
TWI613182B (zh) 2013-02-21 2018-02-01 必治妥美雅史谷比公司 雙環化合物
WO2015073140A1 (en) * 2013-11-14 2015-05-21 Allergan, Inc. 1,3,4-alkenyl oxadiazole amino acid derivatives as sphingosine-1-phosphate receptors' modulators
WO2015108577A1 (en) * 2014-01-15 2015-07-23 Allergan, Inc. Diphenyl urea derivatives as formyl peptide receptor modulators
UY36274A (es) 2014-08-20 2016-02-29 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Compuestos bicíclicos sustituidos como agonistas selectivos de la actividad del receptor s1p1 acoplado a la proteína g
HRP20221417T1 (hr) * 2015-11-13 2023-02-03 Oppilan Pharma Ltd. Heterociklički spojevi za liječenje bolesti
WO2019101511A1 (en) * 2017-11-23 2019-05-31 Basf Se Substituted trifluoromethyloxadiazoles for combating phytopathogenic fungi
CN115197282B (zh) * 2021-04-12 2024-10-11 中科催化新技术(大连)股份有限公司 一种吡喃糖苷衍生物的制备方法
CN115197186B (zh) * 2021-04-12 2024-04-16 中科催化新技术(大连)股份有限公司 一种生物质基吡喃糖苷衍生物的制备方法
CN116375671A (zh) * 2021-12-24 2023-07-04 晶美晟光电材料(南京)有限公司 一种包含四氢吡喃结构的液晶化合物的制备方法
US12612401B2 (en) 2022-07-06 2026-04-28 Oppilan Pharma Limited Crystalline forms of an S1P receptor modulator

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4200750A (en) 1977-01-07 1980-04-29 Westwood Pharmaceuticals Inc. 4-Substituted imidazo [1,2-a]quinoxalines
JPS6480026A (en) 1987-09-21 1989-03-24 Mitsubishi Electric Corp Resist coater
US6069143A (en) 1994-12-20 2000-05-30 Smithkline Beecham Corporation Fibrinogen receptor antagonists
EP1469863A2 (en) 2002-01-18 2004-10-27 Merck & Co., Inc. Selective s1p1/edg1 receptor agonists
DE60329073D1 (de) 2002-01-18 2009-10-15 Merck & Co Inc Edg-rezeptoragonisten
ATE448193T1 (de) 2002-01-18 2009-11-15 Merck & Co Inc ßN-(BENZYL)AMINOALKYL CARBOXYLATE, PHOSPHINATE, PHOSPHONATE UND TETRAZOLE ALS EDG REZEPTORAGONISTENß
JP2005531506A (ja) 2002-03-01 2005-10-20 メルク エンド カムパニー インコーポレーテッド Edg受容体作動薬としてのアミノアルキルホスホネートおよび関連化合物
EP1549640A4 (en) 2002-06-17 2008-08-06 Merck & Co Inc 1 - ((5-ARYL-1,2,4-OXADIAZOL-3-YL) BENZYL) AZETIDINE-3-CARBOXYLATE AND 1 - ((5-ARYL-1,2,4-OXADIAZOL-3-YL) BENZYL) PYRROLIDIN-3-CARBOXYLATE AS EDG RECEPTOR AGONISTS
EP1628967B1 (en) 2003-05-19 2014-04-09 Irm Llc Immunosuppressant compounds and compositions
US7605171B2 (en) * 2003-12-17 2009-10-20 Merck & Co., Inc. (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists
TW200538433A (en) 2004-02-24 2005-12-01 Irm Llc Immunosuppressant compounds and compositiions
WO2005108382A1 (en) 2004-05-04 2005-11-17 Merck & Co., Inc. 1,2,4-oxadiazole derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
CA2583681A1 (en) 2004-10-22 2006-05-04 Merck & Co., Inc. 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as s1p receptor agonists
CA2596990A1 (en) 2005-02-14 2006-08-24 University Of Virginia Patent Foundation Sphingosine 1-phosphate agonists comprising cycloalkanes and 5 -membered heterocycles substituted by amino and phenyl groups
WO2006100633A1 (en) 2005-03-23 2006-09-28 Actelion Pharmaceuticals Ltd NOVEL THIOPHENE DERIVATIVES AS SPHINGOSINE-l-PHOSPHATE-1 RECEPTOR AGONISTS
WO2006115188A1 (ja) * 2005-04-22 2006-11-02 Daiichi Sankyo Company, Limited ヘテロ環化合物
US20080306124A1 (en) 2005-06-08 2008-12-11 Rainer Albert Polycyclic Oxadiazoles or I Soxazoles and Their Use as Sip Receptor Ligands
CN101291908A (zh) 2005-08-23 2008-10-22 Irm责任有限公司 免疫抑制剂化合物和组合物
GB0601744D0 (en) 2006-01-27 2006-03-08 Novartis Ag Organic compounds
WO2007109330A2 (en) 2006-03-21 2007-09-27 Epix Delaware, Inc. S1p receptor modulating compounds
EP2003132B1 (en) 2006-04-03 2014-03-05 Astellas Pharma Inc. Oxadiazole derivatives as S1P1 agonists
JP2009269819A (ja) 2006-08-25 2009-11-19 Asahi Kasei Pharma Kk アミン化合物
AR061841A1 (es) 2006-09-07 2008-09-24 Actelion Pharmaceuticals Ltd Derivados de tiofen-oxadiazoles, agonistas del receptor s1p1/edg1, composiciones farmaceuticas que los contienen y usos como agentes inmunomoduladores.
JP5253401B2 (ja) 2006-09-07 2013-07-31 アクテリオン ファーマシューティカルズ リミテッド 免疫調節薬としてのピリジン−4−イル誘導体
CL2007002594A1 (es) 2006-09-08 2008-06-06 Actelion Pharmaceuticals Ltd Compuestos derivados de piridin-3-il, agentes inmunomoduladores; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de enfermedades asociadas con un sistema inmunologico activado. .
CA2662673A1 (en) 2006-09-21 2008-03-27 Martin Bolli Phenyl derivatives and their use as immunomodulators
RU2009127095A (ru) * 2006-12-15 2011-01-20 Эбботт Лэборетриз (Us) Новые оксадиазольные соединения
GB0625648D0 (en) 2006-12-21 2007-01-31 Glaxo Group Ltd Compounds
US8217027B2 (en) 2006-12-21 2012-07-10 Abbott Laboratories Sphingosine-1-phosphate receptor agonist and antagonist compounds
DK2125797T3 (da) 2007-03-16 2014-02-10 Actelion Pharmaceuticals Ltd Aminopyridinderivater som s1p1/edg1-receptoragonister
EP2014653A1 (en) 2007-06-15 2009-01-14 Bioprojet Novel dicarboxylic acid derivatives as S1P1 receptor agonists
CN101970420B (zh) 2007-10-04 2014-09-24 默克雪兰诺有限公司 噁二唑衍生物
BRPI0818804A2 (pt) 2007-11-01 2015-04-22 Actelion Pharmaceuticals Ltd Composto derivado de pirimidina, composição farmacêutica que o compreende e uso desse composto.
US20110275673A1 (en) 2008-09-19 2011-11-10 Yibin Xiang Inhibitors of sphingosine kinase 1
US20100160369A1 (en) * 2008-12-04 2010-06-24 Exelixis, Inc. S1P1 Agonists and Methods of Making And Using
EP2202232A1 (en) * 2008-12-26 2010-06-30 Laboratorios Almirall, S.A. 1,2,4-oxadiazole derivatives and their therapeutic use
WO2010085581A1 (en) 2009-01-23 2010-07-29 Bristol-Myers Squibb Company Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases
EP2389377B1 (en) 2009-01-23 2014-07-16 Bristol-Myers Squibb Company Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases
ES2405054T3 (es) 2009-01-23 2013-05-30 Bristol-Myers Squibb Company Derivados de pirazol-1,2,4-oxadiazol como agonistas de esfingosina-1-fosfato
US8399451B2 (en) 2009-08-07 2013-03-19 Bristol-Myers Squibb Company Heterocyclic compounds
AU2010319879A1 (en) 2009-10-29 2012-06-14 Bristol-Myers Squibb Company Tricyclic heterocyclic compounds
JP5735634B2 (ja) 2010-04-23 2015-06-17 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company スフィンゴシン−1−リン酸受容体1アゴニストとしての4−(5−イソオキサゾリルまたは5−ピラゾリル−1,2,4−オキサジアゾール−3−イル)−マンデル酸アミド化合物
WO2012040532A1 (en) 2010-09-24 2012-03-29 Bristol-Myers Squibb Company Substituted oxadiazole compounds and their use as s1p1 agonists
JP2013544811A (ja) 2010-11-03 2013-12-19 ブリストル−マイヤーズ スクイブ カンパニー 自己免疫疾患および血管疾患の治療用のs1p1アゴニストとしての複素環式化合物

Similar Documents

Publication Publication Date Title
RU2497822C2 (ru) Селективные к bcl-2 агенты, вызывающие апоптоз, для лечения рака и иммунных заболеваний
JP2012528178A5 (enExample)
JP2017511794A5 (enExample)
JP2018535999A5 (enExample)
JP2005536475A5 (enExample)
JP2011502958A5 (enExample)
JP2016538313A5 (enExample)
JP2004502670A5 (enExample)
JP2020516671A5 (enExample)
JP2019537605A5 (enExample)
RU2011152973A (ru) Индуцирующие апоптоз средства для лечения злокачественной опухоли и иммунных и аутоиммунных заболеваний
JP2014530900A5 (enExample)
JP2007519649A5 (enExample)
JP2014513110A5 (enExample)
JP2017528487A5 (enExample)
JP2010523682A5 (enExample)
JP2011509309A5 (enExample)
JP2007538024A5 (enExample)
JP2019537603A5 (enExample)
RU2007101236A (ru) Новые гидантоиновые производные для лечения обструктивных заболеваний дыхательных путей
JP2015517566A5 (enExample)
JP2010508338A5 (enExample)
JP2018502906A5 (enExample)
JP2009525340A5 (enExample)
JP5788507B2 (ja) 置換3−フェニル−1,2,4−オキサジアゾール化合物